BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rizzetto M, Grotzinger K, Theodore D, Demuth D, Irving WL, Manns M, Roughley A, Forssen UM. Reasons for nonuse of antiviral treatment in patients with chronic hepatitis C infection and thrombocytopaenia: a retrospective chart review from five European countries. J Viral Hepat 2014;21:e129-34. [PMID: 24698004 DOI: 10.1111/jvh.12256] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
Number Citing Articles
1 Maan R, Zaim R, van der Meer AJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Manns MP, Zeuzem S, Hansen BE, Janssen H, Veldt BJ, de Knegt RJ, Uyl-de Groot CA. Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis. J Gastroenterol Hepatol 2016;31:1851-9. [PMID: 26990109 DOI: 10.1111/jgh.13373] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
2 Maan R, de Knegt RJ, Veldt BJ. Management of Thrombocytopenia in Chronic Liver Disease: Focus on Pharmacotherapeutic Strategies. Drugs 2015;75:1981-92. [PMID: 26501978 DOI: 10.1007/s40265-015-0480-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
3 Abdela J. Current Advance in Thrombopoietin Receptor Agonists in the Management of Thrombocytopenia Associated With Chronic Liver Disease: Focus on Avatrombopag. Clin Med Insights Blood Disord 2019;12:1179545X19875105. [PMID: 31673229 DOI: 10.1177/1179545X19875105] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]